HOWL Stock Discussion
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Featured Articles